SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
CordovaCann closed a non-brokered private placement of 3,024,521 common shares at $0.32 per share for gross proceeds of $967,846 (with $415,345 issued in settlement of debt). This is an unregistered equity issuance that dilutes existing shareholders.
View raw filing on EDGAR →CordovaCann closed a non-brokered private placement issuing 6,210,190 common shares at $0.25 per share for gross proceeds of $1,552,548. The securities were not registered under the Securities Act of 1933 and are subject to a four-month hold period under Canadian securities laws.
View raw filing on EDGAR →Monroe Capital Income Plus Corp issued 964,518 shares of common stock at $9.75 per share for an aggregate offering price of $9.4 million pursuant to subscription agreements, with the sale exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →The filing discloses the closing of an underwriter's over-allotment option exercise in connection with the initial public offering of CHAD (Variable Rate Series C Perpetual Preferred Stock), generating $1.65 million in gross proceeds through issuance of 206,250 additional CHAD shares. The Company also announced establishment of a $300 million ATM offering facility for CHAD. These are dilutive equity issuances that provide capital for the Company's treasury strategy, fitting the dilutive_issuance category. While the primary focus is on SOL treasury accumulation, the material capital-raising activity through preferred stock issuance is the actionable disclosure.
View raw filing on EDGAR →Barings Private Credit Corp completed an unregistered sale of 1,104,539.715 shares of common stock for approximately $22.0 million pursuant to subscription agreements with investors, exempt under Section 4(a)(2) and Regulation D/S. This private placement increases the share count and materially affects existing shareholders' ownership percentages and the registrant's capital structure.
View raw filing on EDGAR →La Rosa Holdings entered into a Securities Purchase Agreement on September 15, 2026, to issue 200 shares of Series E Convertible Preferred Stock at $1,000 per share ($200,000 aggregate proceeds) in a private placement under Regulation D Rule 506(b), with an option for additional closings at the same price. This unregistered equity issuance materially dilutes existing shareholders' ownership and voting power.
View raw filing on EDGAR →The exhibit announces receipt of over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants, with an additional USD $573,750 in potential proceeds from 425,000 unexercised warrants. While warrant exercises are technically conversions of existing securities rather than new issuances, they result in dilution to existing shareholders through the creation of additional common shares. The proceeds strengthen the company's balance sheet and extend cash runway, which is material to investors assessing the registrant's financial position and ability to fund operations through pivotal Phase III trial data readout.
View raw filing on EDGAR →The filing discloses unregistered sales of Class A common stock under Item 3.02, with three insiders (CEO James G. Silk, Chief Fiduciary Officer Derek L. Fletcher, and Board member Peter T. Cangany, Jr.) purchasing shares at $1.06 per share pursuant to subscription agreements on September 15, 2026. The securities are exempt from registration under Section 4(a)(2) and Regulation D, which is the hallmark of a private placement. This is a dilutive equity issuance material to investors assessing capital structure and insider confidence.
View raw filing on EDGAR →Draganfly completed a public offering of 7,150,000 common shares (or pre-funded warrants) at US$7.00 per share for gross proceeds of approximately US$50 million pursuant to a shelf registration statement and prospectus supplement.
View raw filing on EDGAR →The exhibit discloses the effectiveness of a Form F-10 registration statement and filing of prospectus supplements qualifying the distribution of 5,828,342 voting shares and warrants issuable upon deemed exercise of special warrants previously issued on July 30, 2026, plus resale registration of those securities. This is a dilutive equity issuance event — the special warrants convert automatically into voting shares and additional warrants, expanding the equity base without cash proceeds to the company. The registration statement and prospectus supplements enable secondary market resales by selling shareholders, which is material to existing shareholders' ownership dilution.
View raw filing on EDGAR →AEye entered into an At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners to offer and sell up to $50 million of common stock through an ATM offering on the Nasdaq Capital Market, replacing a prior ATM agreement. This equity distribution arrangement allows the company to raise capital opportunistically at market prices and materially affects existing shareholders through potential dilution.
View raw filing on EDGAR →The disclosure announces a $15,000,000 rights offering to distribute transferable subscription rights to purchase up to 4,225,352 shares of Class A common stock at a subscription price of $3.55 or higher. This is a dilutive equity issuance that will increase the share count and is material to investors assessing capital structure and ownership dilution. The record date of September 25, 2026 and specific share count and pricing terms confirm this is a concrete equity offering announcement.
View raw filing on EDGAR →FibroBiologics entered into a securities purchase agreement to issue 298,508 shares of common stock and accompanying warrants to its Chief Scientific Officer in a private placement under Section 4(a)(2) and Regulation D Rule 506(b), raising approximately $0.5 million. The unregistered securities materially dilute existing shareholder ownership and voting power.
View raw filing on EDGAR →Jaguar Health issued multiple tranches of equity securities without registration, including 557,377 shares to LAS in exchange for debt cancellation, 304,473 shares to Streeterville in exchange for preferred stock, and 535,000 shares plus a pre-funded warrant for 2,077,255 shares to acquire Napo Therapeutics minority interest. These unregistered private placements under Section 3(a)(9), Section 4(a)(2), and Regulation D Rule 506 collectively represent substantial dilution to existing shareholders.
View raw filing on EDGAR →Tempest Therapeutics entered into a securities purchase agreement on September 11, 2026, for a private placement of pre-funded warrants and common warrants to purchase up to 3,105,591 shares of common stock, generating approximately $2.5 million in gross proceeds with up to ~$5 million in additional proceeds upon warrant exercise. The unregistered offering was conducted under Section 4(a)(2) and Regulation D exemptions and includes lock-up restrictions and registration obligations.
View raw filing on EDGAR →The Trust issued 148,800 shares in private placement transactions to accredited investors under Rule 506(c) of Regulation D, exempt from Securities Act registration. The filing explicitly discloses unregistered equity sales totaling $650,589 in aggregate value, with Grayscale Securities acting as Authorized Participant and potential underwriter. This is a classic dilutive issuance of unregistered equity securities, material to investors assessing share dilution and capital structure.
View raw filing on EDGAR →ONEOK entered into an equity distribution agreement with BofA Securities for up to $1 billion in common stock offerings, amended following the company's corporate reorganization.
View raw filing on EDGAR →XCF Global issued warrants to purchase 6,891,798 shares of Common Stock in a private placement to GL PART SPV II, LLC (controlled by the largest beneficial owner) for $1,000,000 under Section 4(a)(2) and Regulation D Rule 506(b). This is an unregistered equity issuance that dilutes existing shareholders and raises capital, fitting the dilutive_issuance category. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities).
View raw filing on EDGAR →Biodexa announced entry into a warrant exercise transaction involving issuance of new unregistered warrants to purchase 4,408,436 ADSs at $1.05 exercise price in a private placement to an accredited investor. The New Warrants were offered pursuant to an exemption from Securities Act registration and have not been registered, fitting the dilutive_issuance profile. The transaction generates $2.3 million in gross proceeds and creates substantial dilution through warrant inducement, a common capital-raising mechanism at clinical-stage biotech companies.
View raw filing on EDGAR →HealthStream completed a $40 million private placement of 1,355,932 shares of common stock to WJRJJ Ventures at $29.50 per share, issued pursuant to Section 4(a)(2) exemption from Securities Act registration. The company intends to use the proceeds for general corporate purposes, working capital, and potential acquisitions, and the investor received registration rights for resale.
View raw filing on EDGAR →Pulse Biosciences entered into an equity distribution agreement with Mizuho on September 15, 2026, authorizing the sale of up to $85 million in common stock through an at-the-market offering under Rule 415. This follows a prior August 2026 agreement with the same agent under which approximately $68.8 million has already been sold.
View raw filing on EDGAR →The filing discloses conversion of senior secured convertible promissory notes into common stock on two dates in September 2026, resulting in issuance of 1,413,450 aggregate shares to satisfy $465,000 in conversion obligations. The shares were issued to an existing securityholder (Lind) in reliance on Section 3(a)(9) and Section 4(a)(2) exemptions, characteristic of unregistered equity issuances. This represents a material dilutive event affecting shareholder ownership and capital structure.
View raw filing on EDGAR →GT Biopharma entered into a Securities Purchase Agreement on September 14, 2026, to issue up to 8,277.778 shares of Series M 10% Convertible Preferred Stock (with aggregate stated value of $8,277,778 for $7,450,000) plus warrants to purchase common stock equal to 100% of conversion shares, with additional Greenshoe Rights for up to $30,000,000 more. The preferred stock is convertible into common stock at $6.10 per share, and the warrants are exercisable immediately. This is a classic dilutive private placement of convertible securities and warrants, disclosed under Items 1.01 and 3.02, designed to raise capital while creating substantial dilution to existing shareholders through conversion and warrant exercise rights.
View raw filing on EDGAR →XCF Global entered into an At-the-Market (ATM) sales agreement on September 14, 2026, authorizing the issuance of up to $100 million in Class A common stock through Roth Capital Partners and H.C. Wainwright. ATM offerings are equity issuances that dilute existing shareholders and are typically material capital-raising events, particularly for emerging growth companies. The filing explicitly discloses the sales agreement, commission structure (up to 3.0%), and intended use of proceeds for working capital and general corporate purposes.
View raw filing on EDGAR →Fusemachines entered into a Securities Purchase Agreement on September 10, 2026, to issue 2,138,935 shares of common stock to vendors and service providers in satisfaction of approximately $1.30 million in accrued fees. The shares are being issued at $0.6103 per share (VWAP-based pricing) with no cash consideration received by the company. This is a classic dilutive equity issuance to settle liabilities, disclosed under Item 3.02 (Unregistered Sales of Equity Securities) and offered under Section 4(a)(2) and Regulation D exemptions, indicating an unregistered private placement.
View raw filing on EDGAR →Click Holdings entered into an Equity Purchase Agreement on September 14, 2026, with Crom Structured Opportunities Fund I, LP, granting the Investor the right to purchase up to $100 million of the Company's Class A ordinary shares at the Company's discretion over a 36-month commitment period. This is a classic at-the-market (ATM) or structured equity offering arrangement—an unregistered private placement of equity securities that will dilute existing shareholders. The Company also committed to file a registration statement within 30 days to register the maximum number of shares for resale, and agreed to pay $10,000 in investor legal expenses. Such arrangements are material to investors as they signal potential dilution and capital-raising pressure.
View raw filing on EDGAR →Laser Photonics closed a public offering on September 14, 2026, issuing 10,500,000 shares of common stock at $0.75 per share along with Series B-1 and Series B-2 warrants to purchase an additional 21,000,000 shares combined, generating gross proceeds of approximately $7.9 million. This is a material dilutive equity issuance that increases the share count substantially and would significantly affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (a) 2,869,595 shares of common stock from conversion of Series B-1 Preferred Stock, (b) 867,887 shares from conversion of Series B-2 Preferred Stock, (c) warrants to purchase approximately 927,114 shares at $10.30 per share, and (d) pre-funded warrants to purchase approximately 16,932,508 shares. These issuances were approved by stockholders at a special meeting on September 9, 2026, and rely on the Section 4(a)(2) exemption from Securities Act registration, indicating a private placement structure. The aggregate dilution from these securities is material to shareholders.
View raw filing on EDGAR →Dream Finders Homes entered into Subscription Agreements on September 14, 2026, to sell 225,000 shares of Series B Convertible Preferred Stock at $1,000 per share for $225 million in immediate proceeds, with an additional 450,000 shares contingent on merger closing (totaling $675 million potential). The preferred stock is convertible into Class A common stock at a discount (20% post-sixth anniversary, 25% upon covenant breach), making this an unregistered private placement under Section 4(a)(2) that is dilutive to common shareholders.
View raw filing on EDGAR →NuRAN Wireless announced entry into an at-the-market (ATM) offering agreement with H.C. Wainwright & Co. on September 15, 2026, permitting the Company to offer and sell up to US$50,000,000 in common shares at prevailing market prices through Nasdaq. This is a classic dilutive equity issuance under Rule 415(a)(4) of the Securities Act, material to investors as it signals potential dilution and capital-raising activity to fund infrastructure expansion and working capital.
View raw filing on EDGAR →This announcement discloses a secondary public offering of 9,000,000 Class A common shares by a selling shareholder (OCM Njord Holdings S.à r.l., owned by Oaktree Capital Management funds) who beneficially owns approximately 20% of the Company's Class A common shares. While technically a secondary offering (not a primary issuance by the Company itself), the substantial dilution to existing shareholders and the material size of the offering (with an additional 1,350,000 shares under the underwriter's option) make this a material capital-structure event. The Company receives no proceeds, but shareholders face significant dilution from a major shareholder's sale.
View raw filing on EDGAR →The exhibit announces the filing and effectiveness of a base shelf prospectus permitting the issuance of up to US$200 million in voting shares, warrants, units, and subscription receipts over 25 months. It also discloses the deemed exercise of 5,828,342 special warrants (previously placed in July 2026 for US$24.8 million) into voting shares and warrants, creating significant dilution to existing shareholders. While the base shelf itself is a registration framework rather than an immediate issuance, the deemed exercise of the special warrants represents a concrete dilutive event, and the shelf prospectus establishes the mechanism for future dilutive offerings.
View raw filing on EDGAR →This press release announces the completion of a €5.3 million capital increase through issuance of 101,923,092 new shares and 127,403,865 warrants, representing a 29.1% dilution to existing shareholders before warrant exercise and 20.3% after full warrant exercise. The placement was made to institutional investors with removal of preferential subscription rights, a classic dilutive private placement structure. The disclosure explicitly addresses shareholder dilution impact, noting a 1% pre-offering shareholder would hold 0.71% post-issuance and 0.57% if all warrants are exercised.
View raw filing on EDGAR →Enbridge issued 44,735,000 common shares (including full exercise of the over-allotment option) in a public offering at CDN$66.85 per share, generating approximately CDN$3.0 billion in gross proceeds. This is a material registered public offering of equity securities that dilutes existing shareholders and represents a significant capital-raising event material to investors' assessment of the company's capital structure and financing strategy.
View raw filing on EDGAR →XBP Global Holdings entered into securities purchase agreements for a private placement of 2,275,245 shares of common stock at approximately $2.66 per share for aggregate gross proceeds of $6.05 million. The shares are unregistered and issued in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D, with participation from insiders (CEO Jonovic, CFO Avramovic) and related parties (HCI affiliate of HGM, Avenue Capital funds).
View raw filing on EDGAR →Trilogy Metals completed a US$35.6 million strategic equity investment by the U.S. Department of War on September 11, 2026, issuing 8,215,570 units (each consisting of one common share and 0.75 warrants) to the DOW, resulting in the U.S. Government becoming an approximately 10% shareholder. The unregistered securities were issued in a private placement exempt from Securities Act registration under Section 4(a)(2), materially diluting existing shareholders.
View raw filing on EDGAR →Yarrow Bioscience entered into an underwriting agreement on September 10, 2026 to issue and sell 5,769,231 shares of common stock at $26.00 per share, with underwriters exercising a full option for an additional 865,384 shares. The offering is expected to raise approximately $161.8 million in net proceeds. This is a registered public offering of equity securities that will dilute existing shareholders and materially affect the company's capital structure and share count.
View raw filing on EDGAR →PDS Biotechnology completed the initial closing of an $11.3 million PIPE financing led by Nant Capital, issuing 16.5 million shares of common stock, 23.5 million pre-funded warrants, and 20 million common warrants, with an additional $11 million contingent at a milestone closing.
View raw filing on EDGAR →Tilray issued 2,841,650 shares of common stock in unregistered private debt-for-equity exchange transactions between August 31 and September 8, 2026, exchanging them for $12 million principal of convertible notes. This is a dilutive equity issuance relying on Section 3(a)(9) exemption, which is a hallmark disclosure under Item 3.02 and materially affects shareholder equity and ownership structure.
View raw filing on EDGAR →The Amendment modifies the pricing terms of a purchase agreement under which the Company may elect to sell shares of common stock to Chardan Capital Markets LLC. The agreement establishes a framework for potential equity issuances at discounted VWAP prices (97.0%–98.5%), which is characteristic of a dilutive equity facility. While the Amendment itself does not constitute an immediate issuance, it materially alters the terms governing future share sales and represents a material definitive agreement affecting the Company's capital structure and shareholder dilution risk.
View raw filing on EDGAR →First Citizens BancShares filed a Certificate of Designation on September 11, 2026, establishing Series F Preferred Stock and closed a public offering of 300,000 depositary shares on September 14, 2026, representing a $30 billion liquidation preference. The offering, underwritten by major investment banks and bearing a 7.500% perpetual non-cumulative dividend rate, materially dilutes existing common shareholders' ownership and voting power.
View raw filing on EDGAR →Tyra Biosciences entered into an underwriting agreement on September 14, 2026 to issue 9,079,000 shares of common stock at $22.03 per share and 9,078,529 pre-funded warrants, generating approximately $400 million in gross proceeds. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is a material capital-raising event typical of clinical-stage biotech companies. The filing explicitly references the shelf registration statement (Form S-3) and prospectus supplement, confirming this is a registered offering rather than a private placement, but the economic substance—issuance of equity to raise capital—remains a dilutive issuance material to investors.
View raw filing on EDGAR →This exhibit is an ASX Appendix 2A application for quotation of 68,107 ordinary shares issued on vesting of employee performance rights (101,573 performance rights converted). While the immediate issuance is modest in absolute terms, the filing discloses substantial unquoted convertible securities outstanding (45.2M convertible notes, 35M convertible debentures, 21.2M performance rights, 14M options), indicating material dilution potential. The conversion of equity-linked instruments and the disclosure of the capital structure would affect a reasonable investor's assessment of dilution risk.
View raw filing on EDGAR →The Amendment modifies the terms of an ongoing equity purchase agreement under which Hyperliquid Strategies Inc may elect to sell up to 160,000,000+ shares of common stock to Chardan Capital Markets LLC at discounted VWAP-based prices (98.5% and 97.0% of VWAP). This is a dilutive equity issuance arrangement—a private placement or PIPE-like facility—that allows the company to raise capital by selling shares at a discount. The amendment adjusts the pricing mechanism for future tranches, which is material to existing shareholders as it affects the terms and economics of potential dilution.
View raw filing on EDGAR →Treasure Global completed an unregistered sale of equity securities (TGL Shares) relying on Section 4(a)(2) and Regulation S exemptions, with shares issued on a restricted basis subject to Rule 144 resale limitations.
View raw filing on EDGAR →Change Agents Corporation completed multiple dilutive equity-linked capital raises, including issuance of $280,000 principal OID Notes with 1,000,000 pre-funded warrants at $0.0001 exercise price, amendment to an equity line with Hudson Global Ventures for up to $10,000,000 in put shares at $2.00 per share, and issuance of 84,000 additional pre-funded warrants to existing noteholders. All instruments are subject to Nasdaq Rule 5635(d) caps at 19.99% and require stockholder approval, indicating substantial dilution to existing shareholders.
View raw filing on EDGAR →On September 11, 2026, the Company entered into Securities Purchase Agreements for a private placement of 2,703,727 shares of common stock at $1.05 per share for aggregate proceeds of $2,838,911, plus a note conversion by the CEO of 683,725 shares for $717,911 of debt cancellation. The unregistered sale to accredited investors under Section 4(a)(2) and Rule 506 is material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →The filing discloses a private placement of 520,834 shares of common stock at $4.80 per share for approximately $2.5 million in gross proceeds, issued in reliance on Regulation S to a non-U.S. investor (Chan Chun Hong). This is an unregistered sale of equity securities under Item 1.01 and Item 3.02, which is a classic dilutive issuance event. The shares will bear restrictive legends and the company intends to use proceeds for general corporate purposes and potential strategic investments.
View raw filing on EDGAR →AIM ImmunoTech converted approximately $400,000 of debt into 1,749,434 shares of common stock at an average price of $0.228 per share. Item 3.02 explicitly discloses this as an unregistered sale of equity securities under Section 3(a)(9) of the Securities Act. This debt-to-equity conversion is a dilutive issuance that materially increases share count and would affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →CaliberCos issued Series AAA Convertible Preferred Stock in an unregistered transaction exempt under Section 4(a)(2) and Regulation D, with approximately $0.6 million of note principal converted into preferred shares convertible into Class A common stock at specified prices ($2.50, $3.50, $4.50 per share). This unregistered equity issuance will result in dilution to existing shareholders upon conversion.
View raw filing on EDGAR →